FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
By Sarah Tanaka
3 articles tagged "semaglutide"
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
FDA has warned 70+ telehealth companies over compounded GLP-1 drugs, with scrutiny now extending to affiliated medical groups and prescribing networks.
New FAERS analysis finds Wegovy carries nearly fivefold higher ischemic optic neuropathy risk vs. Ozempic, raising ocular safety concerns for GLP-1 drugs.